<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary complications after allogeneic hematopoietic cell transplantation: Evaluation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary complications after allogeneic hematopoietic cell transplantation: Evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary complications after allogeneic hematopoietic cell transplantation: Evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert J Kaner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Dana Zappetti, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2951411410"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allogeneic hematopoietic cell transplantation (HCT, also called hematopoietic stem cell transplantation) is the treatment of choice for many hematologic disorders. Pulmonary complications are a common cause of morbidity and occasionally mortality following this procedure [<a href="#rid1">1-5</a>].</p><p>The pulmonary complications of allogeneic HCT will be reviewed here. The determination of eligibility for HCT, infectious complications of HCT, supportive care following HCT, and pulmonary complications of <strong>autologous</strong> HCT are discussed separately. (See  <a class="medical medical_review" href="/d/html/16870.html" rel="external">"Determining eligibility for allogeneic hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/122403.html" rel="external">"Survival, quality of life, and late complications after hematopoietic cell transplantation in adults"</a> and  <a class="medical medical_review" href="/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H4153690091"><span class="h1">OVERVIEW AND DEFINITIONS</span><span class="headingEndMark"> — </span>Hematopoietic cell transplantation (HCT) is a general term for a variety of procedures in which the patient is treated with chemotherapy and/or irradiation (ie, the "preparative regimen") followed by the infusion of hematopoietic progenitor cells. Progenitor cells can come from a variety of sources (eg, bone marrow, peripheral blood, cord blood). (See  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.)</p><p class="headingAnchor" id="H1573693127"><span class="h2">Allogeneic versus autologous HCT</span><span class="headingEndMark"> — </span>Allogeneic HCT refers to the use of hematopoietic progenitor cells collected from a relative (which can be human leukocyte antigen [HLA] identical, haploidentical, or mismatched) or an unrelated donor (volunteer or umbilical cord donor). Autologous HCT refers to a collection of hematopoietic progenitor cells from the patient prior to the administration of high-dose chemotherapy designed to target an underlying malignancy, followed by reinfusion of these cells. </p><p>Many of the pulmonary complications of allogeneic HCT also occur with autologous HCT, but there are some important differences. Prevention of graft rejection and graft-versus-host disease (GVHD) in allogeneic HCT necessitates more intense immunosuppression than that required for autologous HCT, which does not have these complications. Allogeneic grafts may be associated with development of potentially detrimental GVHD. On the other hand, some allogeneic HCT patients may benefit from a graft-versus-tumor effect. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a> and  <a class="medical medical_review" href="/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"</a>.)</p><p>Autologous HCT is discussed separately. (See  <a class="medical medical_review" href="/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2009409221"><span class="h2">Preparative conditioning regimen</span><span class="headingEndMark"> — </span>Preparative conditioning regimens are designed to ablate or suppress the host bone marrow and thereby prevent graft rejection, but have the potential to cause pulmonary toxicity. Preparative regimens for HCT have been termed myeloablative (eg, total body irradiation ≥5 Gy, high dose <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>), nonmyeloablative (<a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, antithymocyte globulin, irradiation ≤2 Gy), and reduced intensity (eg, low-dose busulfan, <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>). The various preparative conditioning regimens are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2411110652"><span class="h2">Engraftment</span><span class="headingEndMark"> — </span>Engraftment after HCT is defined as the attainment of an absolute neutrophil count (ANC) of 1000/microL, or three consecutive days with a count greater than 500. Time to engraftment is variable and dependent on multiple variables, including cell source, graft composition, and type of conditioning.</p><p>At the time of engraftment of donor hematopoietic cells, patients may develop a cytokine-driven engraftment syndrome. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Engraftment syndrome'</a>.)</p><p class="headingAnchor" id="H1313217008"><span class="h2">Maintenance immunosuppression</span><span class="headingEndMark"> — </span>After allogeneic HCT, maintenance immunosuppression is administered to prevent graft rejection and GVHD. A commonly used regimen is the combination of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and a calcineurin inhibitor such as <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>; alternative or additional agents include post-transplant <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, glucocorticoids, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and also agents targeting T-cell depletion. These agents contribute to the risk of pulmonary toxicity and opportunistic infections. (See  <a class="medical medical_review" href="/d/html/3542.html" rel="external">"Prevention of graft-versus-host disease"</a>.)</p><p class="headingAnchor" id="H1677613890"><span class="h2">Graft-versus-host disease</span><span class="headingEndMark"> — </span>Graft-versus-host disease (GVHD) occurs when immune cells transplanted from a nonidentical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. Hyperacute GVHD, which is very rare with current HLA typing, occurs in the first 14 days post-HCT, acute GVHD in the first 100 days, and chronic GVHD after the first 100 days, although the specific timing is approximate. Despite preconditioning and maintenance immunosuppression to prevent GVHD, a substantial proportion of allogeneic HCT recipients are affected by GVHD. GVHD in turn may increase the risk of certain pulmonary complications, such as the idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, bronchiolitis obliterans, and late-occurring infections. (See  <a class="medical medical_review" href="/d/html/3546.html" rel="external">"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2664491279"><span class="h1">APPROACH TO THE PATIENT WITH RESPIRATORY SYMPTOMS OR SIGNS</span><span class="headingEndMark"> — </span>The approach to evaluating pulmonary complications that occur after allogeneic hematopoietic cell transplantation (HCT) begins with considering the timing of onset of the pulmonary disease (eg, before or after engraftment), the appearance of the chest radiograph (eg, clear, focal opacities, diffuse opacities), and the particular features of the individual patient  (<a class="graphic graphic_table graphicRef83194" href="/d/graphic/83194.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef83195" href="/d/graphic/83195.html" rel="external">table 2</a>). </p><p>The acuity of illness (eg, fever, tachypnea, hypoxemia, leukocyte counts) should guide the rapidity of the evaluation and the need for empiric antibiotics. Almost all febrile HCT recipients are treated empirically with broad-spectrum antibiotics until a causative organism is identified or an alternate diagnosis is confirmed. The choice of empiric therapy should depend upon the risk for specific infections, the potential sites of infection, and the susceptibility patterns at a given institution  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)</p><p>Features that may help direct the evaluation include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Presence of a maculopapular rash, gastrointestinal symptoms, and a rising serum bilirubin can help identify graft-versus-host disease as a cause of interstitial lung disease. (See  <a class="medical medical_review" href="/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)"</a> and  <a class="medical medical_review" href="/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk for certain infections can be predicted based on pretransplant serostatus (eg, cytomegalovirus, herpes simplex virus, HIV, varicella-zoster virus, Epstein-Barr virus, toxoplasmosis), prior exposures (eg, cats, birds, mycobacteria, endemic fungi) of the recipient and donor, and also the history of prophylaxis for infectious agents. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation", section on 'Risk of infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of timing, dose, and field of radiation therapy delivered to the chest to treat the underlying malignancy or as part of the conditioning regimen, as radiation pneumonitis is a potential cause of respiratory symptoms and signs. (See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to drugs that cause pulmonary or cardiac toxicity during the pretransplant treatment of the primary disease. (See  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/4327.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents"</a> and  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a> and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Knowledge of the current and previous immunosuppressive and chemotherapeutic agents (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, glucocorticoids) helps in assessing the risk of opportunistic infection and the likelihood of lung toxicity due to the agents given. (See  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2372715339"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The initial evaluation of pulmonary complications of allogeneic hematopoietic cell transplantation (HCT) typically includes laboratory testing (eg, complete blood counts, blood cultures, peripheral blood and urine tests for bacterial, viral, and fungal antigens or sequences), pulmonary function testing, and imaging studies  (<a class="graphic graphic_table graphicRef83194" href="/d/graphic/83194.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef83195" href="/d/graphic/83195.html" rel="external">table 2</a>). Additional testing is based on the timing of symptom onset, acuity of illness, and the appearance of the chest radiograph.</p><p class="headingAnchor" id="H2071540266"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory testing generally includes assessment of complete blood counts and differential to assess the severity of neutropenia and lymphocytopenia, and also the possibility that anemia is contributing to dyspnea. D-dimer and brain natriuretic peptide levels are sent when thromboembolism or cardiogenic pulmonary edema are suspected.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiologic tests</strong> – Blood cultures are obtained for bacteria and fungi in all HCT recipients with a fever. Nasopharyngeal swabs are sent for polymerase chain reaction (PCR) testing for respiratory viruses (eg, influenza, parainfluenza, respiratory syncytial virus, adenovirus, coronavirus, and others). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; the virus that causes coronavirus disease 2019 [COVID-19]) is among the group of respiratory viral pathogens that can cause pneumonia in the post-HCT period. Urinary Legionella and pneumococcal antigen tests are also obtained. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Cytomegalovirus (CMV) pneumonitis can occur in the post-engraftment phase, so blood is tested for CMV replication (eg, viral load by PCR) in most patients with fever and radiographic opacities after engraftment. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation", section on 'Pneumonia'</a>.)</p><p></p><p class="bulletIndent1">Serum assays for aspergillus galactomannan, beta-D-glucan, and cryptococcus antigen can be obtained, particularly if nodular opacities are noted on imaging. A more detailed discussion of the evaluation for infection following HCT is provided separately. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a> and  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates"</a>.) </p><p></p><p class="bulletIndent1">Lower respiratory tract sampling may be necessary if the above tests are unrevealing and the patient does not respond to empiric therapy. (See <a class="local">'Bronchoscopy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoantibody testing is obtained when rheumatic disease (eg, systemic sclerosis, polymyositis, Sjögren's disease, vasculitis) is suspected on the basis of compatible clinical findings developing late after HCT, Autoimmune disease is rarely reported as a late complication of HCT, most often in patients who received a myeloablative conditioning regimen. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Autoimmune disease'</a>.)</p><p></p><p class="headingAnchor" id="H3627403656"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>A conventional chest radiograph is obtained in virtually all HCT recipients with fever and/or pulmonary symptoms or signs, as the radiographic appearance can help guide the evaluation of pulmonary complications of HCT  (<a class="graphic graphic_table graphicRef83194" href="/d/graphic/83194.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef83195" href="/d/graphic/83195.html" rel="external">table 2</a>).</p><p>In addition, most patients undergo computed tomography (CT), which is more sensitive than a conventional chest radiograph and may identify subtle abnormalities missed on the conventional chest radiograph [<a href="#rid6">6,7</a>]. Chest CT is also used to characterize the patterns of abnormalities (eg, ground glass versus reticular, nodular versus diffuse) and the exact location [<a href="#rid8">8</a>]. However, the specific radiographic pattern is rarely diagnostic, and many of the pulmonary diseases that follow allogeneic HCT can have multiple radiographic appearances.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse pulmonary opacities</strong> – After allogeneic HCT, diffuse pulmonary opacities can be caused by a broad spectrum of disease processes, including bacterial, viral (eg, CMV, influenza), or fungal (eg, <em>Pneumocystis</em>) infection, the engraftment syndrome, the idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, interstitial pneumonia due to connective tissue disease, and pulmonary alveolar proteinosis  (<a class="graphic graphic_table graphicRef83195" href="/d/graphic/83195.html" rel="external">table 2</a>) [<a href="#rid9">9,10</a>]. Many of these disorders are associated with diffuse ground glass opacities, although CMV, <em>Aspergillus</em>, <em>Pneumocystis</em>, organizing pneumonia, and pulmonary cytolytic thrombi can present with diffuse small nodular opacities. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal pulmonary opacities</strong> – Focal or lobar opacities in febrile, allogeneic HCT recipients are often caused by bacterial or fungal infection (eg, Nocardia, aspergillus), but can also be caused by pulmonary thromboembolism or organizing pneumonia. Invasive pulmonary fungal infection should be particularly suspected when there are nodular abnormalities on chest radiograph or CT scan [<a href="#rid8">8,11</a>]. Less common causes of focal radiographic opacities include organizing pneumonia, irradiation pneumonitis (localized to a field of treatment), and recurrent lymphoma.</p><p></p><p class="bulletIndent1">Nodular opacities without associated fever can be caused by processes such as recurrent lymphoma, posttransplant lymphoproliferative disease, and lung cancer [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Malignancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clear chest radiograph</strong> – Following allogeneic HCT, the disease processes that cause dyspnea and a clear conventional chest radiograph include anemia, early <em>Pneumocystis</em> pneumonia, thromboembolic disease, cardiac dysfunction, and airways disease such as bronchiolitis obliterans (BO) [<a href="#rid12">12,13</a>]. <em>Pneumocystis</em> pneumonia and pulmonary veno-occlusive disease may present with a normal chest radiograph, but the chest CT is not normal. Pulmonary thromboembolism (rare) can present with a clear chest radiograph, but the presence of hypoxemia and/or or a positive D-dimer should lead to additional imaging studies. (See  <a class="medical medical_review" href="/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV", section on 'Radiographic findings'</a> and  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary veno-occlusive disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional imaging studies</strong> – When pulmonary thromboembolic disease or pulmonary veno-occlusive disease is suspected (eg, due to a positive D-dimer test, a characteristic pulmonary function test or radiographic pattern, or a degree of hypoxemia out of proportion to the radiographic opacities), either a computed tomography pulmonary angiogram (CTPA) or conventional pulmonary angiogram is obtained. (See  <a class="medical medical_review" href="/d/html/8269.html" rel="external">"Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults", section on 'Venous congestion on chest imaging'</a> and  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Catheter-based pulmonary angiography'</a>.)</p><p></p><p class="headingAnchor" id="H2956208535"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>The evaluation of dyspnea in stable allogeneic HCT recipients without significant hypoxemia or radiographic opacities usually includes full pulmonary function testing with exercise oximetry and/or arterial blood gas analysis [<a href="#rid14">14</a>]. The results are compared with pretransplant values. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a> and  <a class="medical medical_review" href="/d/html/6972.html" rel="external">"Diffusing capacity for carbon monoxide"</a> and  <a class="medical medical_review" href="/d/html/1612.html" rel="external">"Pulse oximetry"</a>.)</p><p>The combination of a restrictive pattern and a gas transfer abnormality on pulmonary function testing suggests that interstitial lung disease may be present. These findings should be further evaluated with imaging studies. An HRCT may be necessary to ensure that findings that are too subtle to identify on a conventional chest radiograph are not missed. (See <a class="local">'Imaging'</a> above.)</p><p>The combination of normal lung volumes with a pulse oxygen saturation and diffusing capacity (DLCO) that are lower than expected based on the HRCT findings suggests processes such as pulmonary hypertension, thromboembolic disease, pulmonary cytolytic thrombi, or veno-occlusive disease. </p><p>An obstructive pattern with forced expiratory volume in one second (FEV<sub>1</sub>) &lt;70 percent may be a nonspecific finding following HCT or may be a manifestation of BO. For patients with suspected BO, spirometry is monitored at one- to three-month intervals; if spirometry is stable for a year, the frequency can be decreased to 6- to 12-month intervals  (<a class="graphic graphic_table graphicRef105278" href="/d/graphic/105278.html" rel="external">table 3</a>) [<a href="#rid15">15</a>]. The management of BO is described separately. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'</a>.)</p><p class="headingAnchor" id="H1638833125"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>An echocardiogram is obtained when cardiac dysfunction is suspected (eg, diffuse opacities consistent with pulmonary edema) or to assess pulmonary artery pressures when pulmonary veno-occlusive disease or pericardial disease are suspected. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary veno-occlusive disease'</a> and  <a class="medical medical_review" href="/d/html/5319.html" rel="external">"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views"</a> and  <a class="medical medical_review" href="/d/html/5298.html" rel="external">"Tissue Doppler echocardiography"</a>.)</p><p class="headingAnchor" id="H260343109"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>The accuracy and predictive value of skin biopsy in the differentiation of engraftment versus GVHD is unclear. (See  <a class="medical medical_review" href="/d/html/13760.html" rel="external">"Cutaneous manifestations of graft-versus-host disease (GVHD)", section on 'Skin biopsy'</a>.)</p><p class="headingAnchor" id="H372508123"><span class="h2">Bronchoscopy</span></p><p class="headingAnchor" id="H3804939102"><span class="h3">Patients with diffuse pulmonary opacities</span><span class="headingEndMark"> — </span>Bronchoscopy with bronchoalveolar lavage (BAL) is usually performed when imaging shows diffuse or widespread opacities, unless cardiogenic pulmonary edema is strongly suspected or the patient has contraindications to the procedure [<a href="#rid5">5,16,17</a>]. </p><p>Bronchoalveolar lavage is performed in an area that appears involved based on the radiographic evaluation. To detect alveolar hemorrhage, three sequential lavages (30 to 60 mL aliquots) are obtained to look for progressively more hemorrhagic returns. Samples of BAL fluid are routinely sent for cell count, white blood cell differential, immunofluorescence studies (eg, <em>Pneumocystis</em>), stains (eg, gram, acid-fast), culture (eg, bacterial, mycobacterial, viral, fungal), and multiplex polymerase chain reaction (PCR) for respiratory viruses. Aspergillus galactomannan antigen is sent when there is concern for fungal infection, especially <em>Aspergillus fumigatus</em>, and cytologic evaluation can help define inflammatory processes and malignancy. Cytology can also quantify the amount of hemosiderin laden macrophages if there is concern for diffuse alveolar hemorrhage. If recurrence of disease is suspected, the BAL can be sent for flow cytometry. (See  <a class="medical medical_review" href="/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a>.)</p><p>Polymerase chain reaction (PCR) testing of BAL fluid is another highly sensitive technique for identifying CMV but may not be specific for active disease. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation", section on 'Pneumonia'</a>.)</p><p>The additional diagnostic value of transbronchial lung biopsy (TBLB) in conjunction with BAL is controversial [<a href="#rid18">18,19</a>]. We base the decision to obtain a TBLB on how well the patient is tolerating the bronchoscopy, whether they have risk factors for bleeding from a TBLB, and how well they would tolerate iatrogenic pneumothorax. Often, TBLB cannot be performed due to thrombocytopenia.</p><p class="headingAnchor" id="H2392909907"><span class="h3">Focal opacities</span><span class="headingEndMark"> — </span>For stable patients with focal opacities on lung imaging, bronchoscopic evaluation may be delayed pending the results of noninvasive cultures, laboratory tests, and empiric antibiotics directed at the most likely infection(s) based on the patient's post HCT phase  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). If the initial cultures and other tests are negative and the patient hasn’t responded to empiric therapy, bronchoscopy is usually performed to obtain BAL and brushing samples from the affected area for cultures, cytology, and possibly flow cytometry. The studies performed on the BAL fluid and endobronchial brushing samples are described above. (See <a class="local">'Patients with diffuse pulmonary opacities'</a> above.)</p><p class="headingAnchor" id="H3279049507"><span class="h2">Lung biopsy</span><span class="headingEndMark"> — </span>Rarely, a surgical lung biopsy is performed when the above blood, imaging, and bronchoscopic studies do not yield an explanation for diffuse pulmonary opacities and the patient is not improving with empiric therapy (eg, antibiotics, diuresis, glucocorticoids) [<a href="#rid10">10,16</a>]. The decision to pursue lung biopsy must weigh the likelihood of identifying a treatable diagnosis with risks of the procedure; multidisciplinary discussion can be invaluable in this setting [<a href="#rid5">5</a>]. Lung biopsy may be performed via video-assisted thoracoscopic surgery (VATS) or open thoracotomy. Samples are obtained from an area of disease activity, as determined by computed tomography and sent for histopathologic analysis and bacterial, mycobacterial, fungal, and viral culture. Special stains for mycobacteria and fungi are performed. (See  <a class="medical medical_review" href="/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Surgical lung biopsy'</a>.)</p><p>In a case series of 35 hematopoietic stem cell recipients with diffuse pulmonary opacities who underwent open lung biopsy, the most common causes were idiopathic interstitial pneumonia (40 percent), cytomegalovirus pneumonia (20 percent), and organizing pneumonia (14 percent) [<a href="#rid10">10</a>]. Drug reactions were diagnosed in 30 percent, some of whom had organizing pneumonia. The idiopathic interstitial pneumonias found in these patients were diffuse alveolar damage (ie, acute interstitial pneumonia) or nonspecific interstitial pneumonia. (See  <a class="medical medical_review" href="/d/html/4369.html" rel="external">"Acute interstitial pneumonia (Hamman-Rich syndrome)"</a> and  <a class="medical medical_review" href="/d/html/4306.html" rel="external">"Treatment and prognosis of nonspecific interstitial pneumonia"</a>.)</p><p>For patients with lung toxicity due to chemotherapeutic agents or radiation therapy, biopsy findings are nonspecific and include diffuse alveolar damage, type II alveolar epithelial cell atypia and hyperplasia, interstitial pneumonitis, and thickening of the interstitium with early fibrosis. There is usually minimal acute inflammation.</p><p class="headingAnchor" id="H149414635"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Several aspects of allogeneic hematopoietic cell transplantation (HCT) contribute to the development of pulmonary disease, including previous treatment of the underlying disease, the pretransplant conditioning regimen (chemotherapy with or without irradiation), engraftment of donor cells, graft-versus-host disease (GVHD), and ongoing immunosuppression. Thus, the pulmonary complications of allogeneic HCT include a broad spectrum of infectious, inflammatory, and neoplastic disorders  (<a class="graphic graphic_table graphicRef83194" href="/d/graphic/83194.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef83195" href="/d/graphic/83195.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach</strong> – The approach to evaluating pulmonary complications begins with considering the timing of onset of the pulmonary disease (eg, before or after engraftment), the appearance of the chest imaging studies (eg, clear, focal opacities, diffuse opacities), and certain patient- and donor-specific features such as cytomegalovirus (CMV) serologic status, exposure to animals and endemic fungi, exposure to pneumotoxic drugs and radiation therapy, the underlying disease, and degree of immunosuppression. (See <a class="local">'Approach to the patient with respiratory symptoms or signs'</a> above and <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotics</strong> – The acuity of illness (eg, fever, tachypnea, hypoxemia, leukocyte counts) should guide the rapidity of the evaluation and the need for empiric antibiotics. Empiric antibiotics are chosen based on the patient's risk for specific infections, the potential sites of infection, the susceptibility patterns at a given institution, and the cost of the various regimens  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). (See <a class="local">'Approach to the patient with respiratory symptoms or signs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The initial evaluation of pulmonary complications of allogeneic HCT typically includes laboratory testing (eg, complete blood counts, brain natriuretic protein [BNP], blood cultures, and also nasopharyngeal swabs, peripheral blood, and urine tests for viral, fungal, pneumococcus and Legionella infection), and a chest radiograph. Additional testing is based on the timing of symptom onset, acuity of illness, and the appearance of the chest radiograph and, in most patients, computed tomography. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart failure</strong> - Cardiac dysfunction may be suspected in the absence of fever, chills, or night sweats, but can present concomitantly with infection; initial assessment includes measurement of brain natriuretic peptide (BNP) and echocardiography. Atrial arrhythmias are very common in this patient population, especially among older adults who undergo transplantation. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary edema'</a> and <a class="local">'Echocardiography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse opacities on lung imaging</strong> – For HCT recipients with diffuse opacities on lung imaging, bronchoscopy with bronchoalveolar lavage (BAL) is usually performed, preferably in an area of radiographic abnormality. Samples are obtained to look for alveolar hemorrhage, to identify potential infectious agents, and for cytologic analysis. The additional diagnostic value of transbronchial biopsy in conjunction with BAL is controversial. (See <a class="local">'Imaging'</a> above and <a class="local">'Patients with diffuse pulmonary opacities'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal opacities on lung imaging</strong> – For HCT recipients with focal opacities on lung imaging, the most likely diagnosis is infection, although organizing pneumonia, radiation pneumonitis, and recurrent lymphoma are included in the differential. After noninvasive cultures and laboratory tests are obtained, empiric antibiotics are initiated based on the infections considered likely for that patient's post-HCT phase  (<a class="graphic graphic_figure graphicRef52716" href="/d/graphic/52716.html" rel="external">figure 1</a>). If the initial cultures and other tests (eg, PCR of nasopharyngeal swabs for viral infection and microbiologic testing of sputum) are negative and the patient hasn't responded to empiric therapy, flexible bronchoscopy is usually performed to obtain samples from the affected area for microbiologic and cytologic studies. (See <a class="local">'Imaging'</a> above and <a class="local">'Focal opacities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical lung biopsy for opacities of unclear origin</strong> – If the etiology of focal or diffuse radiographic opacities remains unclear after the above testing and the patient is not responding to empiric antimicrobial therapy, a surgical lung biopsy may be needed to secure a diagnosis. (See <a class="local">'Lung biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dyspnea and chest radiographs without new opacities</strong> – Patients with dyspnea and chest radiographs without new opacities following allogeneic HCT may have anemia, pulmonary thromboembolic disease, bronchiolitis obliterans, pulmonary veno-occlusive disease, or cardiac dysfunction. Full pulmonary function testing with arterial blood gas analysis or exercise oximetry can help guide the evaluation. High-resolution computed tomography of the chest is more sensitive than the plain chest radiograph and may detect interstitial disease that was not apparent on the chest radiograph. Echocardiography is often performed to assess for pulmonary vascular disease. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Airflow obstruction and bronchiolitis obliterans'</a> and  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Pulmonary veno-occlusive disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of pulmonary complications of allogeneic HCT depends on the specific cause, as described separately. (See  <a class="medical medical_review" href="/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a> and  <a class="medical medical_review" href="/d/html/1401.html" rel="external">"Approach to the immunocompromised patient with fever and pulmonary infiltrates", section on 'Selection of initial therapy'</a>.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med 2004; 25:189.</a></li><li><a class="nounderline abstract_t">Roychowdhury M, Pambuccian SE, Aslan DL, et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch Pathol Lab Med 2005; 129:366.</a></li><li><a class="nounderline abstract_t">Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110:3784.</a></li><li><a class="nounderline abstract_t">Lucena CM, Torres A, Rovira M, et al. Pulmonary complications in hematopoietic SCT: a prospective study. Bone Marrow Transplant 2014; 49:1293.</a></li><li><a class="nounderline abstract_t">Haider S, Durairajan N, Soubani AO. Noninfectious pulmonary complications of haematopoietic stem cell transplantation. Eur Respir Rev 2020; 29.</a></li><li><a class="nounderline abstract_t">Graham NJ, Müller NL, Miller RR, Shepherd JD. Intrathoracic complications following allogeneic bone marrow transplantation: CT findings. Radiology 1991; 181:153.</a></li><li><a class="nounderline abstract_t">Versluys AB, Bierings MB, Beek FJ, et al. High-resolution CT can differentiate between alloimmune and nonalloimmune lung disease early after hematopoietic cell transplantation. AJR Am J Roentgenol 2014; 203:656.</a></li><li><a class="nounderline abstract_t">Wingard JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood 2012; 120:1791.</a></li><li><a class="nounderline abstract_t">Afessa B, Peters SG. Noninfectious pneumonitis after blood and marrow transplant. Curr Opin Oncol 2008; 20:227.</a></li><li><a class="nounderline abstract_t">Wang JY, Chang YL, Lee LN, et al. Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy. Ann Thorac Surg 2004; 78:267.</a></li><li><a class="nounderline abstract_t">Mori M, Galvin JR, Barloon TJ, et al. Fungal pulmonary infections after bone marrow transplantation: evaluation with radiography and CT. Radiology 1991; 178:721.</a></li><li><a class="nounderline abstract_t">Sharma S, Nadrous HF, Peters SG, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385.</a></li><li><a class="nounderline abstract_t">Worthy SA, Flint JD, Müller NL. Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings. Radiographics 1997; 17:1359.</a></li><li><a class="nounderline abstract_t">Milburn HJ, Prentice HG, du Bois RM. Can lung function measurements be used to predict which patients will be at risk of developing interstitial pneumonitis after bone marrow transplantation? Thorax 1992; 47:421.</a></li><li><a class="nounderline abstract_t">Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015; 125:606.</a></li><li><a class="nounderline abstract_t">Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol 2015; 33:501.</a></li><li><a class="nounderline abstract_t">Jorge L, Torres D, Languasco A, et al. Clinical Usefulness of Bronchoalveolar Lavage in the Management of Pulmonary Infiltrates in Adults with Hematological Malignancies and Stem Cell Transplantation. Mediterr J Hematol Infect Dis 2020; 12:e2020025.</a></li><li><a class="nounderline abstract_t">Patel NR, Lee PS, Kim JH, et al. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest 2005; 127:1388.</a></li><li><a class="nounderline abstract_t">Jain P, Sandur S, Meli Y, et al. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125:712.</a></li></ol></div><div id="topicVersionRevision">Topic 128427 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15062610" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737032" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671231" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25046219" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary complications in hematopoietic SCT: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32581138" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Noninfectious pulmonary complications of haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1887025" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intrathoracic complications following allogeneic bone marrow transplantation: CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148172" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High-resolution CT can differentiate between alloimmune and nonalloimmune lung disease early after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22692506" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300774" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Noninfectious pneumonitis after blood and marrow transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223441" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1994408" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fungal pulmonary infections after bone marrow transplantation: evaluation with radiography and CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162733" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397451" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary complications after bone marrow transplantation: high-resolution CT and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1496500" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Can lung function measurements be used to predict which patients will be at risk of developing interstitial pneumonitis after bone marrow transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398933" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : How we treat chronic graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32395214" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical Usefulness of Bronchoalveolar Lavage in the Management of Pulmonary Infiltrates in Adults with Hematological Malignancies and Stem Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821221" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769756" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
